AYLİN REZVANİ
(Bezmialem Vakıf Üniversitesi)
İLKNUR AKTAŞ
(Sağlık Bilimleri Üniversitesi)
NURETTİN TAŞTEKİN
(Trakya Üniversitesi)
Reyhan ÇELİKER
(Acıbadem Üniversitesi)
SELDA SARIKAYA
(Zonguldak Bülent Ecevit Üniversitesi)
ERBİL DURSUN
(Kocaeli Üniversitesi)
ŞENAY ÖZDOLAP ÇOBAN
(Zonguldak Bülent Ecevit Üniversitesi)
NİGAR DURSUN
(Kocaeli Üniversitesi)
COŞKUN ZATERİ
(Çanakkale Onsekiz Mart Üniversitesi)
LALE ALTAN İNCEOĞLU
(Bursa Uludağ Üniversitesi)
Murat BİRTANE
(Trakya Üniversitesi)
KENAN AKGÜN
(İstanbul Üniversitesi)
NECDET SÜT
(Trakya Üniversitesi)
Yıl: 2019Cilt: 6Sayı: 3ISSN: 2148-4902 / 2536-4553Sayfa Aralığı: 254 - 259İngilizce

105 0
Nephrolithiasis in ankylosing spondylitis and its relationship with disease assessment scales
OBJECTIVE: The aim of this study was to investigate the frequency of renal calculi in patients with ankylosing spondylitis (AS) and to determine its relationship with disease assessment variables. METHODS: The study was designed retrospectively, and it included a cohort of 320 patients with AS diagnosed using the Modified New York Criteria. A total of 119 patients who underwent renal ultrasonography (USG), in who the erythrocyte sedimentation rate, C-reactive protein, blood calcium, phosphorus, Vitamin D, parathormone, and urinary calcium excretion were measured, and who also had lateral cervical and lumbar radiography in the same time period were extracted from the cohort. All patients’ demographic characteristics and the results of blood and urine tests were recorded. The Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Mobility Index (BASMI), and Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) were evaluated in all patients. RESULTS: Thirteen of the 119 patients had renal calculi confirmed by USG data. The frequency of nephrolithiasis detected by USG was 10.9% in patients with AS. The disease lasted significantly longer in patients with renal calculi ([nephrolithiasis (+): 18.39±8.72 years; nephrolithiasis (−): 12.02±8.43 years, p=0.01]). The BASMI total score was significantly higher in the group of patients with renal calculi. There was not any significant difference in terms of blood samples, HLA-B27, BASDAI, BASFI, and mSASSS between groups. CONCLUSION: The frequency of renal stones is increased in patients with AS compared to healthy population. Especially patients who had AS for a long time and higher BASMI values are more susceptible to renal calculi. It is important to point out that the results of this type of studies would be more reliable if the study is conducted on large patient groups and population-based prevalence
Fen > Tıp > Genel ve Dahili Tıp
DergiAraştırma MakalesiErişime Açık
  • 1. Gran JT, Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 1993;22:319–34. [CrossRef ]
  • 2. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53:650–7. [CrossRef ]
  • 3. Vilar MJ, Cury SE, Ferraz MB, Sesso R, Atra E. Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 1997;26:19–23. [CrossRef ]
  • 4. Korkmaz C, Ozcan A, Akçar N. Increased frequency of ultrasonographic findings suggestive of renal stones in patients with ankylosing spondylitis. Clin Exp Rheumatol 2005;23:389–92.
  • 5. Otunctemur A, Ozbek E, Cakir SS, Dursun M, Polat EC, Ozcan L, et al. Urolithiasis is associated with low serum testosterone levels in men. Arch Ital Urol Androl 2015;87:83–6. [CrossRef ]
  • 6. Muslumanoglu AY, Binbay M, Yuruk E, Akman T, Tepeler A, Esen T, et al. Updated epidemiologic study of urolithiasis in Turkey. I: Changing characteristics of urolithiasis. Urol Res 2011;39:309–14. [CrossRef ]
  • 7. Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R. Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 2007;34:371–3.
  • 8. Lui NL, Carty A, Haroon N, Shen H, Cook RJ, Inman RD. Clinical correlates of urolithiasis in ankylosing spondylitis. J Rheumatol 2011;38:1953–6. [CrossRef ]
  • 9. Cansu DU, Calışır C, Savaş Yavaş U, Kaşifoğlu T, Korkmaz C. Predictors of radiographic severity and functional disability in Turkish patients with ankylosing spondylitis. Clin Rheumatol 2011;30:557–62.
  • 10. Resorlu M, Gokmen F, Resorlu H, Adam G, Aylanc N, Akbal A, et al. Prospective evaluation of the renal morphology and vascular resistance in patients with ankylosing spondylitis. Med Ultrason 2015;17:180–4.
  • 11. Gönüllü E, Bilge NŞY, Cansu DU, Bekmez M, Musmul A, Akçar N, et al. Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospectivecase-control study. Urolithiasis 2017;45:353–7. [CrossRef ]
  • 12. Jakobsen AK, Jacobsson LT, Patschan O, Askling J, Kristensen LE. Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS One 2014;9:e113602. [CrossRef ]
  • 13. Fallahi S, Jamshidi AR, Gharibdoost F, Mahmoud MI, Paragomi P, Nicknam MH, et al. Urolithiasis in ankylosing spondylitis: Correlation with Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis metrology index (BASMI). Caspian J Intern Med 2012;3:508–13.
  • 14. Shih MT, Tang SH, Cha TL, Wu ST, Chiang JH, Chen WC. The Risk of Nephrolithiasis Among Patients With Ankylosing Spondylitis: a Population-Based Cohort Study. Arch Rheumatol 2016;31:346–52.
  • 15. Khan SR. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol 2014;3:256–76.
  • 16. Toussirot E, Wendling D. Osteoporosis in ankylosing spondylitis. [Article in French]. Presse Med 1996;25:720–4.
  • 17. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8. [CrossRef ]
  • 18. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASASWorking Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951–4.
  • 19. Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int 2005;25:280–4. [CrossRef ]
  • 20. Karatepe AG, Akkoc Y, Akar S, Kirazli Y, Akkoc N. The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity. Rheumatol Int 2005;25:612–8. [CrossRef ]
  • 21. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.
  • 22. Creemers MC, Franssen MJ, van’t Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127–9.
  • 23. Canales BK, Leonard SM, Singh JA, Orzano IM, Zimmermann B, Weiland D, et al. Spondyloarthropathy: an independent risk factor for kidney stones. J Endourol 2006;20:542–6. [CrossRef ]
  • 24. Incel NA, Gökoğlu F, Nacir B, Incel N. Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis. Clin Rheumatol 2006;25:667–70. [CrossRef ]
  • 25. Drach GW. Urinary lithiasis. In: Campbell’s urology, vol II. Saunders, Philadelphia; 1986; p. 1094.
  • 26. Gambaro G, Fabris A, Abaterusso C, Cosaro A, Ceol M, Mezzabotta F, et al. Pathogenesis of nephrolithiasis: recent insight from cell biology and renal pathology. Clin Cases Miner Bone Metab 2008;5:107–9.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.